Loading...
Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.
Journal Title
Journal of obesity and weight-loss medication
Keywords
Readers/Advisors
Journal Title
Term and Year
Publication Date
2015-05-06
Book Title
Publication Volume
1
Publication Issue
1
Publication Begin
Publication End
Number of pages
Collections
Files
Loading...
jowm-1-004.pdf
Adobe PDF, 268.94 KB
Research Projects
Organizational Units
Journal Issue
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control and cardiometabolic risk factors in adults with type 2 diabetes mellitus, but pediatric data is sparse.
This is the first report to describe the effects of GLP-1 receptor agonist Exenatide on metabolic risk and weight in adolescents with morbid obesity (BMI>35kg/m) and type 2 diabetes in the first 6 months after treatment initiation. Two patients with morbid obesity who failed conventional therapy with insulin glargine and Metformin were treated with the addition of Exenatide. Metabolic parameters were obtained at 3 and 6 months post intervention.
Improvements in cardiometabolic risk factors, such as fasting glucose and triglyceride levels, as well as HbA1c, were reached at 6 months compared to baseline.
Our cases highlight the therapeutic potential of exenatide for adolescent patients with morbid obesity and type 2 diabetes.
This is the first report to describe the effects of GLP-1 receptor agonist Exenatide on metabolic risk and weight in adolescents with morbid obesity (BMI>35kg/m) and type 2 diabetes in the first 6 months after treatment initiation. Two patients with morbid obesity who failed conventional therapy with insulin glargine and Metformin were treated with the addition of Exenatide. Metabolic parameters were obtained at 3 and 6 months post intervention.
Improvements in cardiometabolic risk factors, such as fasting glucose and triglyceride levels, as well as HbA1c, were reached at 6 months compared to baseline.
Our cases highlight the therapeutic potential of exenatide for adolescent patients with morbid obesity and type 2 diabetes.
Citation
Censani M, Chin VL, Fennoy I. Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports. J Obes Weight Loss Medicat. 2015;1(1):004. doi: 10.23937/2572-4010.1510004. Epub 2015 May 6. PMID: 27182560; PMCID: PMC4864000.